Table 3.

Acute and Late Toxicity, CTCAE v 5.0

	Whole Cohort, n=86 n (%)	No Prior RT, n=68 n (%)	Prior RT, n=18 n (%)
Acute Grade 3
Mucositis	13 (15%)	12 (18%)	1 (6%)
Peg	5 (6%)	3 (4%)	1 (6%)
Dermatitis	6 (7%)	3 (4%)	2 (11%)
Fatigue	1 (1%)	1 (1%)	0
Soft tissue necrosis	1 (1%)	1 (1%) flap failure	0
	Total: 18 (21%) patients	Total: 16 (24%) patients	Total: 2 (11%) patients
Late Grade 3
Vision loss	2 (2%)	2 (3%)	0
Osteoradionecrosis	1 (1%)	1 (1%)	0
Facial pain	1 (1%)	0 (0%)	1 (6%)
Brain necrosis	1 (1%)	0	1 (6%)
Soft tissue necrosis	1 (1%)	1 (1%) flap failure	0
Soft tissue fibrosis	1 (1%)	1 (1%)	0
	Total: 5 (6%) patients	Total: 3 (4%) patients	Total: 2 (11%) patients
Late Grade 1–2
Brain necrosis	11 (13%)	5 (7%)	6 (33%)
Osteoradionecrosis	5 (6%)	2 (3%)	3 (17%)
Soft tissue necrosis	2 (2%)	1 (1%)	1 (6%)
Watering eyes	15 (17%)	15 (22%)	0
Trismus	5 (6%)	3 (4%)	2 (11%)
Blurred vision	2 (2%)	1 (1%)	1 (6%)
Glaucoma	1 (1%)	1 (1%)	0
Cataracts	2 (2%)	2 (3%)	0
Nasal congestion	5 (6%)	4 (6%)	1 (6%)
Lymphedema	1 (1%)	0	1 (6%)
Oral cavity fistula	1 (1%)	1 (1%)	0
Ear disorder	3 (3%)	2 (3%)	1 (6%)
Sinus disorder	4 (5%)	3 (4%)	1 (6%)
Epistaxis	1 (1%)	1 (1%)	0
	Total: 42 (49%) patients	Total: 32 (47%) patients	Total: 10 (50%) patients